{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:49:14Z","timestamp":1791071354641,"version":"4.1.0"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The in vitro activity of caspofungin (CAS) was investigated against 28 yeast isolates belonging to\n                    <jats:italic>Candida albicans<\/jats:italic>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    = 5),\n                    <jats:italic>Candida guilliermondii<\/jats:italic>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    = 10), and\n                    <jats:italic>Candida parapsilosis<\/jats:italic>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    = 13). CAS MICs obtained by broth dilution and Etest methods clearly showed a rank order of susceptibility to the echinocandin compound with\n                    <jats:italic>C. albicans<\/jats:italic>\n                    &gt;\n                    <jats:italic>C. parapsilosis<\/jats:italic>\n                    &gt;\n                    <jats:italic>C. guilliermondii<\/jats:italic>\n                    . Similarly, time-kill assays performed on selected isolates showed that CAS was fungistatic against\n                    <jats:italic>C. albicans<\/jats:italic>\n                    and\n                    <jats:italic>C. parapsilosis<\/jats:italic>\n                    , while it did not exert any activity against\n                    <jats:italic>C. guilliermondii<\/jats:italic>\n                    . In a murine model of systemic candidiasis, CAS given at doses as low as 1 mg\/kg of body weight\/day was effective at reducing the kidney burden of mice infected with either\n                    <jats:italic>C. albicans<\/jats:italic>\n                    or\n                    <jats:italic>C. guilliermondii<\/jats:italic>\n                    isolates. Depending on the isolate tested, mice infected with\n                    <jats:italic>C. parapsilosis<\/jats:italic>\n                    responded to CAS given at 1 and\/or 5 mg\/kg\/day. However, the overall CFU reduction for\n                    <jats:italic>C. guilliermondii<\/jats:italic>\n                    and\n                    <jats:italic>C. parapsilosis<\/jats:italic>\n                    was approximately 100-fold less than that for\n                    <jats:italic>C. albicans<\/jats:italic>\n                    . Our study shows that CAS was active in experimental systemic candidiasis due to\n                    <jats:italic>C. guilliermondii<\/jats:italic>\n                    and\n                    <jats:italic>C. parapsilosis<\/jats:italic>\n                    , but this activity required relatively high drug dosages.\n                  <\/jats:p>","DOI":"10.1128\/aac.00111-06","type":"journal-article","created":{"date-parts":[[2006,7,26]],"date-time":"2006-07-26T14:17:58Z","timestamp":1153923478000},"page":"2719-2727","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":81,"title":["Effects of Caspofungin against\n                    <i>Candida guilliermondii<\/i>\n                    and\n                    <i>Candida parapsilosis<\/i>"],"prefix":"10.1128","volume":"50","author":[{"given":"Francesco","family":"Barchiesi","sequence":"first","affiliation":[{"name":"Istituto di Malattie Infettive e Medicina Pubblica, Universita\u0300 Politecnica delle Marche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Spreghini","sequence":"additional","affiliation":[{"name":"Istituto di Malattie Infettive e Medicina Pubblica, Universita\u0300 Politecnica delle Marche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Tomassetti","sequence":"additional","affiliation":[{"name":"Istituto di Malattie Infettive e Medicina Pubblica, Universita\u0300 Politecnica delle Marche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Della Vittoria","sequence":"additional","affiliation":[{"name":"Istituto di Malattie Infettive e Medicina Pubblica, Universita\u0300 Politecnica delle Marche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Arzeni","sequence":"additional","affiliation":[{"name":"Istituto di Malattie Infettive e Medicina Pubblica, Universita\u0300 Politecnica delle Marche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Manso","sequence":"additional","affiliation":[{"name":"Laboratorio di Microbiologia, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I\u00b0-Lancisi-Salesi, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Scalise","sequence":"additional","affiliation":[{"name":"Istituto di Malattie Infettive e Medicina Pubblica, Universita\u0300 Politecnica delle Marche"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2333"},{"key":"e_1_3_1_3_2","first-page":"302","volume":"18","year":"1999","unstructured":"Barchiesi, F., A. M. Schimizzi, A. W. Fothergill, G. Scalise, and M. G. Rinaldi. 1999. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur. J. Clin. Microbiol. Infect. Dis.18:302-304.","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2326"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14472-8"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4453-4456.2004"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2471"},{"key":"e_1_3_1_8_2","first-page":"121","volume":"20","year":"2003","unstructured":"Espinel-Ingroff, A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol.20:121-136.","journal-title":"Rev. Iberoam. Micol."},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.9.1937"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1382-1383.2004"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3616-3623.2005"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5058-5068.2005"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021585"},{"key":"e_1_3_1_14_2","unstructured":"National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeast 2nd ed. Approved standard M27-A2. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.8.3475-3482.2004"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3149-3154.2003"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.11.5425-5427.2005"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.10.4419-4431.2004"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.1068-1071.2003"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.17.2.268-280.2004"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.6.2729-2735.2005"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/499057"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/323401"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040446"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00111-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00111-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T14:13:21Z","timestamp":1645452801000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00111-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1128\/AAC.00111-06"],"URL":"https:\/\/doi.org\/10.1128\/aac.00111-06","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1033638.388862","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"2006-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-05-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}